Jeff Aronin discusses why Paragon Biosciences’ unique company incubator approach results in an 80%–90% approval rate on new drug applications, far exceeding that of the traditional pharma industry. Read more about Jeff Aronin’s take on life science innovation here: https://chiefexecutive.net/how-one-ceo-is-changing-life-sciences-innovation